Company profile
WAVE LIFE SCIENCES, INC.
NASDAQ:WVEBiotechnology: Pharmaceutical Preparations
Drug pipeline (3)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SUVODIRSEN | phase2_3 | — | 2 | completed, terminated |
| LEXANERSEN SODIUM | phase1_2 | — | 2 | terminated |
| ROVANERSEN | phase1_2 | — | 2 | terminated |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (14)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06186492 | phase1 | completed | 2023-11-14 | 2025-02-13 | Wave Life Sciences USA, Inc. | A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) |
| NCT06842186 | phase1_2 | recruiting | 2025-01-31 | 2027-12-01 | Wave Life Sciences USA, Inc. | A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity |
| NCT06405633 | phase1_2 | active_not_recruiting | 2024-07-19 | 2026-09-01 | Wave Life Sciences USA, Inc. | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD |
| NCT03907072 | phase2_3 | terminated | 2019-09-04 | 2019-12-16 | Wave Life Sciences USA, Inc. | Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT07209332 | phase2 | enrolling_by_invitation | 2025-12-28 | 2029-03-01 | Wave Life Sciences USA, Inc. | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy |
FDA applications (0)
No records yet.